WO2021233433A1 - Anticorps monoclonal anti-protéine de spicule du sars-cov-2 - Google Patents

Anticorps monoclonal anti-protéine de spicule du sars-cov-2 Download PDF

Info

Publication number
WO2021233433A1
WO2021233433A1 PCT/CN2021/095228 CN2021095228W WO2021233433A1 WO 2021233433 A1 WO2021233433 A1 WO 2021233433A1 CN 2021095228 W CN2021095228 W CN 2021095228W WO 2021233433 A1 WO2021233433 A1 WO 2021233433A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
seq
acid sequence
variable region
chain variable
Prior art date
Application number
PCT/CN2021/095228
Other languages
English (en)
Chinese (zh)
Inventor
刘培
丁莉丹
阳露
陈晖�
Original Assignee
南京金斯瑞生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 南京金斯瑞生物科技有限公司 filed Critical 南京金斯瑞生物科技有限公司
Priority to CN202180036738.1A priority Critical patent/CN115698058A/zh
Publication of WO2021233433A1 publication Critical patent/WO2021233433A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Definitions

  • the invention belongs to the field of virus detection, diagnosis and treatment, and relates to an anti-SARS-CoV-2 spike protein monoclonal antibody.
  • the invention also relates to a preparation method and application of the anti-SARS-CoV-2 spike protein monoclonal antibody.
  • Severe Acute Respiratory Syndrome Coronavirus 2 (Severe Acute Respiratory Syndrome Coronavirus 2, SARS-CoV-2) is a positive-stranded single-stranded RNA virus with an envelope, belonging to the family of Coronavirus, type B coronavirus, belonging to Severe Acute Respiratory Syndrome Sign related coronavirus species. It can invade the human body through the upper respiratory tract of humans, and use ACE2 expressed on the surface of a variety of cells as receptors to achieve infection. The main infected organs include the lungs, heart, kidneys and other major organs. This resulted in an outbreak of COVID-19 (COVID-19) at the end of 2019. To date, more than 5 million COVID-19 cases and nearly 330,000 deaths have been reported to WHO.
  • SARS-CoV-2 Similar to SARS-CoV, SARS-CoV-2 also uses its highly glycosylated spike protein S (Spike protein, S protein) to complete host cell receptor binding and virus infection in the form of a trimer.
  • S protein has two subunits, S1 and S2.
  • the receptor-binding domain (RBD) region of the S1 subunit can recognize and bind the host cell's angiotensin-converting enzyme 2 (hACE2).
  • the S2 subunit mediates the membrane fusion between the virus and the host cell.
  • the binding of RBD to the hACE2 receptor may cause the S1 protein to fall off from the S2 protein, and promote S2-mediated virus-host membrane fusion and virus infection.
  • mAb Blocking monoclonal antibody
  • One aspect of the present invention provides a monoclonal antibody or functional fragment thereof against the spike protein of SARS-CoV-2, the antibody or functional fragment thereof comprising a heavy chain variable region and a light chain variable region, wherein
  • the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3,
  • the HCDR1 comprises an amino acid sequence selected from SEQ ID NO: 22, 28, 34, 40, 46, 52, 58, 64, 70, or 76 or the amino acid sequence shown includes at most three (e.g., one, two Or three) variants of amino acid mutations;
  • the HCDR2 comprises an amino acid sequence selected from SEQ ID NO: 23, 29, 35, 41, 47, 53, 59, 65, 71 or 77 or the amino acid sequence shown comprises Variants with at most three (for example, one, two or three) amino acid mutations;
  • the HCDR3 comprises a variant selected from SEQ ID NO: 24, 30, 36, 42, 48, 54, 60, 66, 72, or 78
  • the amino acid sequence shown or the amino acid sequence shown contains up to three (for example, one, two, or three) amino acid mutations; and
  • the light chain variable region includes LCDR1, LCDR2 and LCDR3,
  • the LCDR1 sequence includes an amino acid sequence selected from SEQ ID NO: 25, 31, 37, 43, 49, 55, 61, 67, 73 or 79 or the amino acid sequence shown includes at most three (e.g., one, two One or three) variants of amino acid mutations;
  • the LCDR2 sequence comprises an amino acid sequence selected from SEQ ID NO: 26, 32, 38, 44, 50, 56, 62, 68, 74 or 80 or the amino acid sequence shown
  • the sequence contains at most three (for example, one, two or three) variants of amino acid mutations;
  • the LCDR3 sequence contains selected from SEQ ID NO: 27, 33, 39, 45, 51, 57, 63, 69, 75 Or the amino acid sequence shown in 81 or the amino acid sequence shown contains at most three (for example, one, two or three) amino acid mutation variants.
  • the monoclonal antibody or functional fragment thereof wherein the HCDR1 sequence comprises SEQ ID NO: 22, 28, 34, 40, 46, 52, 58, 64, 70 Or the amino acid sequence shown in 76; the HCDR2 sequence includes an amino acid sequence selected from SEQ ID NO: 23, 29, 35, 41, 47, 53, 59, 65, 71, or 77; the HCDR3 sequence includes the selected From the amino acid sequence shown in SEQ ID NO: 24, 30, 36, 42, 48, 54, 60, 66, 72 or 78; and
  • the LCDR1 sequence includes an amino acid sequence selected from SEQ ID NO: 25, 31, 37, 43, 49, 55, 61, 67, 73, or 79;
  • the LCDR2 sequence includes an amino acid sequence selected from SEQ ID NO: 26, 32 , 38, 44, 50, 56, 62, 68, 74 or 80;
  • the LCDR3 sequence comprises an amino acid sequence selected from SEQ ID NO: 27, 33, 39, 45, 51, 57, 63, 69, 75 Or the amino acid sequence shown in 81.
  • the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 are selected from the following sequences:
  • HCDR1, HCDR2, and HCDR3 respectively comprise the amino acid sequence shown in SEQ ID NO: 22, 23 and 24 or the amino acid sequence shown respectively includes at most three (for example, one, two or three) amino acid mutations.
  • LCDR1, LCDR2, and LCDR3 respectively comprise the amino acid sequence shown in SEQ ID NO: 25, 26, and 27 or the amino acid sequence shown respectively includes at most three (for example, one, two or three) amino acid mutation variants ;
  • HCDR1, HCDR2, and HCDR3 respectively comprise the amino acid sequence shown in SEQ ID NO: 28, 29 and 30 or the amino acid sequence shown includes at most three (for example, one, two or three) amino acid mutations.
  • LCDR1, LCDR2, and LCDR3 respectively comprise the amino acid sequence shown in SEQ ID NO: 31, 32, and 33 or the amino acid sequence shown respectively includes at most three (for example, one, two or three) amino acid mutation variants ;
  • the HCDR1, HCDR2, and HCDR3 respectively comprise the amino acid sequence shown in SEQ ID NO: 34, 35 and 36 or the amino acid sequence shown respectively includes at most three (for example, one, two or three) amino acid mutations.
  • LCDR1, LCDR2, and LCDR3 respectively include the amino acid sequence shown in SEQ ID NO: 37, 38, and 39 or the shown amino acid sequence includes at most three (for example, one, two, or three) amino acid mutations ;
  • the HCDR1, HCDR2, and HCDR3 respectively comprise the amino acid sequence shown in SEQ ID NO: 40, 41 and 42 or the amino acid sequence shown respectively includes at most three (for example, one, two or three) amino acid mutations.
  • LCDR1, LCDR2, and LCDR3 respectively comprise the amino acid sequence shown in SEQ ID NOs: 43, 44 and 45 or the shown amino acid sequence respectively include at most three (for example, one, two or three) amino acid mutation variants ;
  • the HCDR1, HCDR2 and HCDR3 respectively comprise the amino acid sequence shown in SEQ ID NO: 46, 47 and 48 or the amino acid sequence shown respectively includes at most three (for example, one, two or three) amino acid mutations.
  • LCDR1, LCDR2, and LCDR3 respectively include the amino acid sequence shown in SEQ ID NO: 49, 50, and 51 or the shown amino acid sequence includes at most three (for example, one, two, or three) amino acid mutations ;
  • the HCDR1, HCDR2, and HCDR3 respectively comprise the amino acid sequence shown in SEQ ID NO: 52, 53 and 54 or the amino acid sequence shown includes at most three (for example, one, two or three) amino acid mutations.
  • Body; and LCDR1, LCDR2, and LCDR3 respectively comprise the amino acid sequence shown in SEQ ID NO: 55, 56 and 57 or the shown amino acid sequence respectively comprise at most three (for example, one, two or three) amino acid mutation variants ;
  • the HCDR1, HCDR2, and HCDR3 respectively comprise the amino acid sequence shown in SEQ ID NO: 58, 59 and 60 or the amino acid sequence shown includes at most three (for example, one, two or three) amino acid mutations.
  • LCDR1, LCDR2, and LCDR3 respectively include the amino acid sequence shown in SEQ ID NO: 61, 62, and 63 or the shown amino acid sequence includes at most three (for example, one, two, or three) amino acid mutations ;
  • the HCDR1, HCDR2 and HCDR3 respectively comprise the amino acid sequence shown in SEQ ID NO: 64, 65 and 66 or the amino acid sequence shown respectively includes at most three (for example, one, two or three) amino acid mutations.
  • LCDR1, LCDR2, and LCDR3 respectively comprise the amino acid sequence shown in SEQ ID NO: 67, 68, and 69 or the amino acid sequence shown respectively includes at most three (for example, one, two or three) amino acid mutation variants ;
  • the HCDR1, HCDR2, and HCDR3 respectively comprise the amino acid sequence shown in SEQ ID NO: 70, 71 and 72 or the amino acid sequence shown includes at most three (for example, one, two or three) amino acid mutations.
  • LCDR1, LCDR2, and LCDR3 respectively comprise the amino acid sequence shown in SEQ ID NO: 73, 74 and 75 or the amino acid sequence shown respectively includes at most three (for example, one, two or three) amino acid mutation variants ;or
  • the HCDR1, HCDR2 and HCDR3 respectively comprise the amino acid sequence shown in SEQ ID NO: 76, 77 and 78 or the amino acid sequence shown respectively includes at most three (for example, one, two or three) amino acid mutations.
  • LCDR1, LCDR2, and LCDR3 respectively comprise the amino acid sequence shown in SEQ ID NO: 79, 80, and 81 or the amino acid sequence shown respectively includes at most three (for example, one, two or three) amino acid mutation variants .
  • the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 are selected from the following sequences:
  • HCDR1, HCDR2 and HCDR3 respectively comprise the amino acid sequences shown in SEQ ID NOs: 22, 23 and 24, and LCDR1, LCDR2 and LCDR3 respectively comprise the amino acid sequences shown in SEQ ID NOs: 25, 26 and 27;
  • HCDR1, HCDR2 and HCDR3 respectively comprise the amino acid sequences shown in SEQ ID NOs: 28, 29 and 30 and LCDR1, LCDR2 and LCDR3 respectively comprise the amino acid sequences shown in SEQ ID NOs: 31, 32 and 33;
  • HCDR1, HCDR2 and HCDR3 respectively comprise the amino acid sequences shown in SEQ ID NOs: 34, 35 and 36 and LCDR1, LCDR2 and LCDR3 respectively comprise the amino acid sequences shown in SEQ ID NOs: 37, 38 and 39;
  • HCDR1, HCDR2 and HCDR3 comprise the amino acid sequences shown in SEQ ID NOs: 40, 41 and 42, and LCDR1, LCDR2 and LCDR3 comprise the amino acid sequences shown in SEQ ID NOs: 43, 44 and 45, respectively;
  • the HCDR1, HCDR2 and HCDR3 respectively comprise the amino acid sequences shown in SEQ ID NOs: 46, 47 and 48 and the LCDR1, LCDR2 and LCDR3 respectively comprise the amino acid sequences shown in SEQ ID NOs: 49, 50 and 51;
  • HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences shown in SEQ ID NOs: 52, 53, and 54 respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences shown in SEQ ID NOs: 55, 56 and 57, respectively;
  • the HCDR1, HCDR2 and HCDR3 respectively comprise the amino acid sequences shown in SEQ ID NOs: 58, 59 and 60 and LCDR1, LCDR2 and LCDR3 respectively comprise the amino acid sequences shown in SEQ ID NOs: 61, 62 and 63;
  • the HCDR1, HCDR2 and HCDR3 respectively comprise the amino acid sequences shown in SEQ ID NOs: 64, 65 and 66 and the LCDR1, LCDR2 and LCDR3 comprise the amino acid sequences shown in SEQ ID NOs: 67, 68 and 69 respectively;
  • the HCDR1, HCDR2 and HCDR3 respectively comprise the amino acid sequences shown in SEQ ID NOs: 70, 71 and 72 and LCDR1, LCDR2 and LCDR3 respectively comprise the amino acid sequences shown in SEQ ID NOs: 73, 74 and 75; or
  • the HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences shown in SEQ ID NOs: 76, 77, and 78, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences shown in SEQ ID NOs: 79, 80, and 81, respectively.
  • the monoclonal antibody or functional fragment thereof, wherein the heavy chain variable region sequence includes SEQ ID NO: 2, 4, 6, 8, 10, 12, 14,
  • the amino acid sequence shown in 16, 18 or 20 has at least 80% (for example, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) identical amino acid sequences; and
  • the light chain variable region sequence comprises at least 80% (for example, 80%, 81%, and the amino acid sequence shown in SEQ ID NO: 3, 5, 7, 9, 11, 13, 15, 17, 19 or 21). 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% , 99%) identical amino acid sequence.
  • the monoclonal antibody or functional fragment thereof wherein the heavy chain variable region sequence comprises SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16 , 18 or 20; and the light chain variable region sequence comprises the amino acid sequence shown in SEQ ID NO: 3, 5, 7, 9, 11, 13, 15, 17, 19 or 21.
  • the monoclonal antibody or functional fragment thereof, wherein the heavy chain variable region and the light chain variable region are selected from the following sequences:
  • the heavy chain variable region contains at least 80% (for example, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%) of the sequence shown in SEQ ID NO: 2 , 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) identical amino acid sequence
  • the light chain variable region Contains at least 80% of the sequence shown in SEQ ID NO: 3 (e.g., 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) identical amino acid sequences;
  • the heavy chain variable region contains at least 80% (for example, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%) of the sequence shown in SEQ ID NO: 4 , 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) identical amino acid sequence
  • the light chain variable region Contains at least 80% of the sequence shown in SEQ ID NO: 5 (e.g., 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) identical amino acid sequences;
  • the heavy chain variable region contains at least 80% (for example, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%) of the sequence shown in SEQ ID NO: 6 , 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) identical amino acid sequence
  • the light chain variable region Contains at least 80% of the sequence shown in SEQ ID NO: 7 (e.g., 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) identical amino acid sequences;
  • the heavy chain variable region contains at least 80% (for example, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%) of the sequence shown in SEQ ID NO: 8 , 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) identical amino acid sequence
  • the light chain variable region Contains at least 80% of the sequence shown in SEQ ID NO: 9 (e.g., 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) identical amino acid sequences;
  • the heavy chain variable region contains at least 80% (for example, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%) of the sequence shown in SEQ ID NO: 10 , 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) identical amino acid sequence
  • the light chain variable region Contains at least 80% of the sequence shown in SEQ ID NO: 11 (e.g., 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) identical amino acid sequences;
  • the heavy chain variable region contains at least 80% (for example, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%) of the sequence shown in SEQ ID NO: 12 , 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) identical amino acid sequence
  • the light chain variable region Contains at least 80% of the sequence shown in SEQ ID NO: 13 (e.g., 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) identical amino acid sequences;
  • the heavy chain variable region contains at least 80% (for example, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%) of the sequence shown in SEQ ID NO: 14 , 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) identical amino acid sequence
  • the light chain variable region Contains at least 80% of the sequence shown in SEQ ID NO: 15 (e.g., 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) identical amino acid sequences;
  • the heavy chain variable region contains at least 80% (for example, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%) of the sequence shown in SEQ ID NO: 16 , 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) identical amino acid sequence
  • the light chain variable region Contains at least 80% of the sequence shown in SEQ ID NO: 17 (e.g., 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) identical amino acid sequences;
  • the heavy chain variable region contains at least 80% (for example, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%) of the sequence shown in SEQ ID NO: 18 , 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) identical amino acid sequence
  • the light chain variable region Contains at least 80% of the sequence shown in SEQ ID NO: 19 (e.g., 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) identical amino acid sequence; or
  • the heavy chain variable region contains at least 80% (for example, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%) of the sequence shown in SEQ ID NO: 20 , 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) identical amino acid sequence
  • the light chain variable region Contains at least 80% of the sequence shown in SEQ ID NO: 21 (e.g., 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) identical amino acid sequences.
  • the monoclonal antibody or functional fragment thereof, wherein the heavy chain variable region and the light chain variable region are selected from the following sequences:
  • the heavy chain variable region includes the amino acid sequence shown in SEQ ID NO: 2, and the light chain variable region includes the amino acid sequence shown in SEQ ID NO: 3;
  • the heavy chain variable region includes the amino acid sequence shown in SEQ ID NO: 4, and the light chain variable region includes the amino acid sequence shown in SEQ ID NO: 5;
  • the heavy chain variable region includes the amino acid sequence shown in SEQ ID NO: 6, and the light chain variable region includes the amino acid sequence shown in SEQ ID NO: 7;
  • the heavy chain variable region includes the amino acid sequence shown in SEQ ID NO: 8, and the light chain variable region includes the amino acid sequence shown in SEQ ID NO: 9;
  • the heavy chain variable region includes the amino acid sequence shown in SEQ ID NO: 10, and the light chain variable region includes the amino acid sequence shown in SEQ ID NO: 11;
  • the heavy chain variable region includes the amino acid sequence shown in SEQ ID NO: 12, and the light chain variable region includes the amino acid sequence shown in SEQ ID NO: 13;
  • the heavy chain variable region includes the amino acid sequence shown in SEQ ID NO: 14, and the light chain variable region includes the amino acid sequence shown in SEQ ID NO: 15;
  • the heavy chain variable region includes the amino acid sequence shown in SEQ ID NO: 16, and the light chain variable region includes the amino acid sequence shown in SEQ ID NO: 17;
  • the heavy chain variable region comprises the amino acid sequence shown in SEQ ID NO: 18, and the light chain variable region comprises the amino acid sequence shown in SEQ ID NO: 19; or
  • the heavy chain variable region includes the amino acid sequence shown in SEQ ID NO: 20, and the light chain variable region includes the amino acid sequence shown in SEQ ID NO: 21.
  • the monoclonal antibody is a rabbit monoclonal antibody, or a humanized antibody or a fully human antibody based on the rabbit monoclonal antibody.
  • the present invention provides an isolated polynucleotide, which encodes the anti-SARS-CoV-2 spike protein monoclonal antibody or functional fragment thereof.
  • the polynucleotide of the present invention comprises a nucleotide sequence encoding the heavy chain variable region of the monoclonal antibody or functional fragment thereof, and a nucleotide sequence encoding the monoclonal antibody or functional fragment thereof The nucleotide sequence of the light chain variable region.
  • the present invention provides an expression vector comprising the polynucleotide.
  • the present invention provides a host cell or cell-free expression system comprising the expression vector.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising the anti-SARS-CoV-2 spike protein monoclonal antibody or functional fragment thereof and a pharmaceutically acceptable carrier.
  • the present invention further provides the application of the anti-SARS-CoV-2 spike protein monoclonal antibody or its functional fragments in the preparation of drugs for treating coronavirus.
  • the coronavirus is selected from SARS-CoV, MERS-Cov or SARS-Cov-2, preferably SARS-Cov-2.
  • the present invention provides a kit for detecting coronavirus, which contains the anti-SARS-CoV-2 spike protein monoclonal antibody or functional fragment thereof of the present invention.
  • the coronavirus is selected from SARS-CoV, MERS-Cov or SARS-Cov-2, preferably SARS-Cov-2.
  • the anti-SARS-CoV-2 spike protein monoclonal antibody of the present invention can specifically bind to the S protein, and can effectively block the combination of the S protein and the ACE2 protein, and specifically prevent the virus from infecting human cells.
  • the ACE2 protein can prevent the S protein from invading human ACE2 overexpressing cells.
  • the monoclonal antibody of the present invention can also be used for the detection of SARS-CoV-2S-RBD cells.
  • the monoclonal antibody provided by the present invention can recognize 4 kinds of epitopes of the antigen, and the diversity of the antibody provides convenience for the development of the detection kit.
  • Figure 1 The results of rabbit serum titer detection after immunization.
  • Figure 2 Rabbit monoclonal antibodies (BS-R2B2, BS-R2B17, 4G6, 12D3, 39G6) specifically bind to S recombinant protein.
  • Figure 3 Rabbit monoclonal antibody (BS-R2B2, BS-R2B17, 4G6, 12D3, 39G6) blocking the binding of S protein and ACE2 protein.
  • FIG. 4 Rabbit monoclonal antibodies (BS-R2B2, BS-R2B17) prevent SARS-CoV-2 pseudovirus from entering human ACE2 overexpressing cells.
  • FIG. 5 Rabbit monoclonal antibodies (BS-R2B17, 12D3) specifically bind to cell lines expressing S protein by flow cytometry.
  • Figure 6 Pairing curve diagram of monoclonal antibody BS-R2B30 and BS-R1B8.
  • new coronavirus SARS-CoV-2
  • 2019-nCoV belongs to the ⁇ -coronavirus, has an envelope, and the particles are round or elliptical, often pleomorphic, with a diameter of 60-140nm . Its genetic characteristics are significantly different from SARSr-Cov and MERSr-CoV. Studies have shown that it has more than 85% homology with bat SARS-like coronavirus (bat-SL-CoVZC45). When isolated and cultured in vitro, 2019-nCov can be found in human respiratory epithelial cells in about 96 hours, while isolation and culture in Vero E6 and Huh-7 cell lines takes about 6 days.
  • antibody is intended to refer to an immunoglobulin molecule consisting of four polypeptide chains (two heavy chains (H) and two light chains (L) are connected to each other by disulfide bonds (ie, "complete antibody molecules")) , And its multimers (for example, IgM) or antigen-binding fragments thereof.
  • Each heavy chain is composed of a heavy chain variable region ("HCVR” or "VH”) and a heavy chain constant region (composed of domains CH1, CH2, and CH3).
  • Each light chain is composed of a light chain variable region ("LCVR or "VL”) and a light chain constant region (CL).
  • VH and VL regions can be further subdivided into hypervariable regions called complementarity determining regions (CDR), There is a more conserved region inserted in between called the framework region (FR).
  • CDR complementarity determining regions
  • FR framework region
  • Each VH and VL consists of three CDRs and four FRs, arranged in the following order from the amino terminus to the hydroxyl terminus: FR1, CDR1, FR2, CDR2, FR3 , CDR3, FR4.
  • the FR of the antibody may be the same as the human germline sequence or may be naturally or artificially modified.
  • the term "monoclonal antibody” refers to a uniform antibody that only targets a specific epitope. In contrast to a typical ordinary polyclonal antibody preparation that includes different antibodies directed against different epitopes (epitopes), each monoclonal antibody is directed against a single epitope on the antigen.
  • the modifier “monoclonal” refers to the uniform characteristics of an antibody, and is not interpreted as an antibody that needs to be produced by any specific method.
  • the monoclonal antibodies of the present invention are preferably produced by recombinant DNA methods or obtained by screening methods described elsewhere in the present invention.
  • isolated polynucleotide refers to a polynucleotide that does not exist naturally in nature, including polynucleotides isolated from nature (including living organisms) through biological techniques, and also includes artificially synthesized polynucleotides.
  • the isolated polynucleotide can be genomic DNA, cDNA, mRNA or other synthetic RNA, or a combination thereof. It should be pointed out that, based on the amino acid sequences of the heavy chain variable region and the light chain variable region provided herein, those skilled in the art can design cores whose nucleotide sequences are not completely identical based on the codon degeneracy. Nucleotide sequences, but they all encode the same amino acid sequence. These modified nucleotide sequences are also included in the scope of the present invention.
  • vector refers to any molecule (for example, nucleic acid, plasmid, virus, etc.) used to transfer nucleotide coding information into a host cell.
  • expression vector or "expression cassette” refers to a vector suitable for expressing a target gene (nucleotide sequence to be expressed) in a host cell, and usually includes a target gene, a promoter, a terminator, a marker gene and other parts.
  • host cell refers to a cell that has been or is capable of being transformed with a nucleic acid sequence and thereby expressing a selected gene of interest.
  • the term includes the offspring of the parent cell, regardless of whether the offspring is the same in morphology or genetic composition as the original parent cell, as long as the offspring has the selected target gene.
  • Commonly used host cells include bacteria, yeast, and mammalian cells.
  • antibody functional fragment means an antigen-binding fragment of an antibody and antibody analogs, which usually include at least part of the antigen-binding region or variable region (for example, one or more CDRs) of a parental antibody. Antibody fragments retain at least some of the binding specificity of the parent antibody.
  • antibody fragments capable of binding to the Coronary Disease Spike (S) protein or part thereof including but not limited to sdAb (single domain antibody), Fab (for example, antibody obtained by papain digestion), F(ab') 2 ( For example, obtained by pepsin digestion), Fv or scFv (for example, obtained by molecular biology techniques).
  • pharmaceutically acceptable carrier includes any and all solvents, dispersants, coatings, antibacterial and antifungal agents, isotonic and sustained release agents, and the like that are compatible with drug administration. Suitable carriers are described in the standard reference documents in the latest edition of Remington’s Pharmaceutical Sciences, which are incorporated herein by reference in their entirety. Examples of suitable carriers or diluents include, but are not limited to, water, saline solution, ringer's solution, glucose solution, and 5% human serum albumin. Liposomes and hydrophobic-aqueous media such as fixed oils can also be used. The use of media and agents for pharmaceutically active substances is well known in the art. Except for those conventional media or reagents that are incompatible with the active ingredients, its use in the ingredients can achieve the desired effect.
  • amino acid substitution refers to the replacement of existing amino acid residues with different amino acid residues in a predetermined (initial) amino acid sequence.
  • amino acid substitution refers to the replacement of existing amino acid residues with different amino acid residues in a predetermined (initial) amino acid sequence.
  • those skilled in the art recognize that a single amino acid substitution in a non-essential region of a polypeptide does not substantially change the biological activity (see, for example, Watson et al., Molecular Biology of the Gene, The Benjamin/Cummings Pub.Co ., p. 224 (fourth edition, 1987)).
  • Such exemplary substitutions are preferably carried out in accordance with the substitutions shown below:
  • the "percent (%) amino acid sequence identity" of a peptide or polypeptide sequence is defined as comparing the sequences and introducing gaps when necessary to obtain the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity.
  • Candidates The percentage of amino acid residues in the sequence that are identical to the amino acid residues in the specific peptide or polypeptide sequence. Sequence comparisons can be performed in a variety of ways within the skill of the art to determine percent amino acid sequence identity, for example, using publicly available computer software, such as BLAST, BLAST-2, ALIGN, or Megalign (DNASTAR) software. Those skilled in the art can determine the appropriate parameters for measuring the comparison, including any algorithm required to obtain the maximum comparison over the entire length of the sequence being compared.
  • administering and “treatment” are used to refer to animals, humans, experimental subjects, cells, tissues, organs, or biological fluids, it means to combine exogenous drugs, therapeutic agents, diagnostic agents or compositions with animals, humans, and recipients. Contact with the person being treated, cells, tissues, organs or biological fluids.
  • administering can refer to, for example, treatment methods, pharmacokinetic methods, diagnostic methods, research methods, and experimental methods. Treating cells includes contacting the reagent with the cell and contacting the reagent with a fluid, where the fluid is in contact with the cell.
  • administering and “treatment” also mean the treatment of cells in vitro and ex vivo, for example, by reagents, diagnostic agents, binding compositions, or by other cells.
  • subject refers to an animal in need of alleviation, prevention and/or treatment of a disease or condition such as a viral infection, preferably a mammal, more preferably a human.
  • a disease or condition such as a viral infection, preferably a mammal, more preferably a human.
  • the term includes human subjects who have a coronavirus such as SARS-CoV-2 infection or are at risk of having a coronavirus such as SARS-CoV-2 infection.
  • the term "effective amount” as used herein refers to an amount that can produce function or activity on humans and/or animals and can be accepted by humans and/or animals.
  • “Pharmaceutically acceptable carrier” refers to a carrier for administration, including various excipients, diluents and buffers, etc. These substances are suitable for human and/or animal administration without excessive adverse side effects, and at the same time It is suitable for maintaining the vitality of the drug or active agent located therein.
  • Example 1 Preparation of anti-SARS-CoV-2 S protein rabbit monoclonal antibody based on single B cell platform
  • Recombinant protein S-RBD-His (sequence shown in SEQ ID NO:1) is used as the animal immune antigen.
  • Female New Zealand white rabbits were immunized with 200 ⁇ g S-RBD-His. Subsequently, the immunization was repeated every 2 weeks to boost the New Zealand white rabbits for a total of 3 times.
  • 3 New Zealand white rabbits titer after three immunizations are up to 105 or more.
  • One rabbit (7316) showing the highest antibody titer ( Figure 1) was subjected to single B cell selection or fusion 4 days after the last immunization.
  • the rabbit spleen was extracted and homogenized to produce a single cell suspension.
  • the plasma B cells were enriched according to the following steps, and single B cells that could secrete SARS-CoV-2 S protein antibody were sorted using the Beacon platform. a. Resuspend the cells in 0.5ml PBS and add 50 ⁇ l (5%) goat serum to block for 5min; b. Add 5 ⁇ g/ml biotin-anti-mouse IgG polyclonal antibody and incubate at room temperature for 15min; c. Continue to add 100 ⁇ l Selection Cocktail (Stemcell ); d. Mix and incubate at room temperature for 15 minutes; e. According to EasySep TM (Stem Cell.
  • Biotin Positive protocol https://www.stemcell.com/easysep-biotin-positive-selection-kit-ii.html )
  • Obtain plasma B cells f. Put the obtained plasma B cells on the Beacon machine and use OptoSelect 14,000 chips;
  • Screen positive clones on the chip Use Antigen Beads to screen positive clones;
  • Example 2 Preparation of anti-SARS-CoV-2 S protein rabbit monoclonal antibody based on the hybridoma platform
  • the rabbit spleen of step (1) of Example 1 was extracted and homogenized to produce a single cell suspension, and at the same time, a single cell suspension of myeloma cells (SP2/0) was prepared.
  • the fused cells were resuspended in 150ml of DMEM/10%FBS medium containing hybridoma cell selection agents thymidine, hypoxanthine and aminopterin, and transferred to 15 ⁇ 96 wells with a volume of 100 ⁇ l with a pipette In the board.
  • the plates were incubated in 5% CO 2 at 37°C. After 10 days of culture, the indirect ELISA described below was used to screen hybridomas that could secrete antibodies against the S protein, and the methods described below were used for RNA extraction and PCR amplification.
  • Indirect ELISA was used to evaluate the binding ability of antibodies in the supernatant to S protein.
  • the ELISA plate was coated with 100 ⁇ l/well of 1 ⁇ g/ml recombinant S protein in PBS at 4° C. overnight.
  • the plate was washed with PBS-T (0.05% Tween), and blocked with 200 ⁇ l/well of PBST containing 1% BSA at 37° C. for 0.5 hour. Then the blocking solution was discarded, 100 ⁇ l of hybridoma cell culture supernatant was added to each plate, and then incubated at room temperature for 1 hour.
  • the plate was washed three times with PBST, and incubated with 100 ⁇ l/well of horseradish peroxidase-conjugated goat anti-rabbit IgG (Fab-specific) (GenScript) at 37°C for 0.5 hours.
  • the plate was washed five times with PBST, then TMB color developing solution (GenScript) was added and incubated in the dark at room temperature for 15 minutes.
  • the reaction was terminated by adding 50 ⁇ l of 1M HCl stop solution (Sigma). Use a microplate reader to read the plate at 450nm.
  • RNA was extracted by Trizol method and reverse transcribed into cDNA.
  • the method of homologous recombination was used to amplify DNA fragments containing light chain variable region + constant region and heavy chain variable region + constant region, and insert them separately In the pcDNA expression vector, an expression plasmid is formed.
  • Example 3 Sequencing of variable region of rabbit monoclonal antibody and recombinant production of antibody
  • Example 1 and Example 2 1) Transform the expression plasmids constructed in Example 1 and Example 2 into competent cells, shake the bacteria for 3-4 hours, directly pipette 100 ⁇ L of bacterial solution into the plate, cover the plate, and take it to a bench shaker for 3 minutes . Take the coated plate back to the ultra-clean workbench, and then place the plate in a 37°C water-proof constant temperature incubator overnight for 12-16 hours. Pick a single colony of shake bacteria, and sequence.
  • V-region nucleotide/protein sequences of clones BS-R2B2, BS-R2B7, BS-R1B8, BS-R1B12, BS-R2B15, BS-R2B17, BS-R2B30, 4G6, 12D3 and 39G6 were obtained.
  • the amino acid sequence of the variable region of the antibody is as follows:
  • BS-R2B2 heavy chain variable region amino acid sequence (SEQ ID NO: 2):
  • BS-R2B2 light chain variable region amino acid sequence (SEQ ID NO: 3):
  • BS-R2B7 heavy chain variable region amino acid sequence (SEQ ID NO: 4):
  • BS-R2B7 light chain variable region amino acid sequence (SEQ ID NO: 5):
  • BS-R1B8 heavy chain variable region amino acid sequence (SEQ ID NO: 6):
  • BS-R1B8 light chain variable region amino acid sequence (SEQ ID NO: 7):
  • BS-R2B12 heavy chain variable region amino acid sequence (SEQ ID NO: 8):
  • BS-R2B15 heavy chain variable region amino acid sequence (SEQ ID NO: 10):
  • the CDR sequences of the antibody heavy chain and light chain are shown in Table 1.
  • the purified antibody was analyzed by SDS-PAGE with a 10% precast gel (GenScript) on the BioRad electrophoresis system.
  • the gel was stained with Estin2.0 (GenScript) and the molecular size and purity were estimated by comparing the stained band with Protein Ladder (GenScript).
  • Indirect ELISA is used to evaluate the binding ability of purified antibodies to S protein.
  • the ELISA plate was coated with 100 ⁇ l/well of 0.5 ⁇ g/ml recombinant S protein in PBS at 4° C. overnight.
  • the plate was washed with PBS-T (0.05% Tween) and blocked with 250 ⁇ l/well of PBST containing 1% BSA at 37°C for 2 hours. Then the blocking solution was discarded, and 100 ⁇ l of purified antibody of 1 ⁇ g/ml was added to the first well, and diluted in a 3-fold gradient, a total of 11 test concentration gradients and 1 zero well. Then incubate for 1 hour at room temperature.
  • the plate was washed three times with PBST, and incubated with 100 ⁇ l/well of horseradish peroxidase-conjugated goat anti-rabbit IgG (Fc specific) (GenScript) at 37°C for 0.5 hours.
  • the plate was washed 4 times with PBST, then TMB color developing solution (GenScript) was added and incubated in the dark at room temperature for 15 minutes.
  • the reaction was terminated by adding 50 ⁇ l of 1M HCl stop solution. Use a microplate reader to read the plate at 450nm.
  • the EC 50 of each clone is as follows:
  • Example 5 Monoclonal antibody blocks the binding of S protein and ACE2 protein
  • the ELISA plate was coated with 100 ⁇ l/well of 0.5 ⁇ g/ml recombinant human ACE2 protein in PBS at 4° C. overnight. The plate was washed with PBST (0.05% Tween) and blocked with 250 ⁇ l/well of PBST containing 1% BSA at 37°C for 2 hours. Then the blocking solution was discarded, and 50 ⁇ l of 3 ⁇ g/ml purified antibody to be tested was added to the first test well, and diluted in a 3-fold gradient, a total of 11 test concentration gradients and 1 zero well.
  • PBST 0.05% Tween
  • the SARS-CoV-2 S-RBD plasmid was transfected into 293F cells by the PEI method. After 60 hours, the cells were collected and washed with PBS. The cells were fixed with 4% PFA for 15 minutes at 4°C, and the membrane was permeabilized with 0.5 mg/ml saponin for 15 minutes at room temperature. Then wash the cells, add anti-SARS-CoV-2 S-RBS antibody (10 ⁇ g/ml), and incubate at 4°C for 40 minutes. Incubate with Alexa Flour 488 conjugated goat anti-rabbit IgG (3 ⁇ g/ml) secondary antibody at 4°C for 30 minutes. The cells were analyzed by flow cytometry, and the data was analyzed by FlowJob analysis software.
  • clones can be used for flow cytometry.
  • clonal antibodies such as BS-R2B17 and 12D3 can be used to detect SARS-CoV-2 S-RBD 293F cells overexpressing SARS-CoV-2.
  • 97.8% of overexpressing SARS-CoV-2 S-RBD 293F cells can be specifically bound by BS-R2B17, indicating that the prepared rabbit monoclonal antibodies against SARS-CoV-2 S-RBD can be used to express SARS-CoV-2 S- Detection of RBD cells.
  • ELISA Competitive ELISA was used to evaluate the epitope of purified antibodies.
  • the ELISA plate was coated with 100 ⁇ l/well of 0.5 ⁇ g/ml recombinant S protein in PBS at 4° C. overnight.
  • the plate was washed with PBS-T (0.05% Tween) and blocked with 250 ⁇ l/well of PBST containing 1% BSA at 37°C for 2 hours. Then the blocking solution was discarded, and a pair (50 ⁇ l of one labeled biotin test antibody and 50 ⁇ l (10 ⁇ g/ml) of purified antibody) were added to each well for competition experiment. Then incubate at 37°C for 1 hour.
  • the plate was washed 3 times with PBST, and incubated with 100 ⁇ l/well of streptavidin HRP (SA-HRP, GenScript) at 37°C for 15 minutes.
  • the plate was washed four times with PBST, then TMB color developing solution (GenScript) was added and incubated at 25°C in the dark for 15 minutes. Stop the reaction by adding 50 ⁇ l of 1M HCl stop solution.
  • Judgment criteria For example, the OD of the self-competitive well of the supernatant BS-R2B30 is 0.545. Compared with the value of 0 well, the difference of the OD value is close to 1.0, which has obvious competitive effect.
  • the difference between the OD value of the supernatant BS-R2B12 and the supernatant BS-R2B30-HRP mixture is about 0.9, there is a clear competitive effect. Therefore, it can be determined that the supernatant BS-R2B30 and the supernatant BS-R2B12 recognize the same epitope.
  • the difference between the OD value of the supernatant BS-R2B17 and the supernatant BS-R2B30-HRP mixture is not significantly different from the value of 0 wells, and there is no competitive effect. Therefore, it can be determined that the supernatant BS-R2B17 and the supernatant BS-R2B30 recognize different epitopes of the antigen.
  • BS-R2B30 BS-R2B12 is an epitope (epitope 1)
  • BS-R2B17 is an epitope (epitope 2)
  • BS-R2B2, 12D3, 4G6, 39G6 is an epitope (epitope 3)
  • BS- R1B8 is an epitope (epitope 4).
  • Sandwich ELISA is used to evaluate the paired detection of purified antibodies.
  • the ELISA plate was coated with 100 ⁇ l/well of 1 ⁇ g/ml purified antibody in PBS at 4° C. overnight.
  • the plate was washed with PBS-T (0.05% Tween) and blocked with 250 ⁇ l/well of PBST containing 1% BSA at 37°C for 2 hours. Then the blocking solution was discarded, and a series of diluted SARS-CoV-2 S-RBD of different concentrations were added to each well, and then incubated at 37°C for 1 hour, and the plate was washed with PBS-T (0.05% Tween).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention relève du domaine de la détection, du diagnostic et du traitement des virus et, concerne en particulier, un anticorps monoclonal anti-protéine de spicule (S) du SARS-CoV-2, son procédé de préparation et son utilisation. La présente invention concerne un anticorps monoclonal anti-protéine S du SARS-CoV-2, et des séquences d'acides aminés d'une région variable de chaîne lourde et d'une région variable de chaîne légère de celui-ci. L'anticorps monoclonal anti-protéine S du SARS-CoV-2 selon l'invention peut se lier de manière spécifique à la protéine S, bloquer de manière efficace la liaison de la protéine S à la protéine ACE2, et empêcher plus particulièrement le virus d'infecter des cellules humaines. L'anticorps monoclonal anti-protéine S du SARS-CoV-2 selon l'invention offre une possibilité et une commodité pour le traitement et la détection du virus du SARS-CoV-2.
PCT/CN2021/095228 2020-05-22 2021-05-21 Anticorps monoclonal anti-protéine de spicule du sars-cov-2 WO2021233433A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202180036738.1A CN115698058A (zh) 2020-05-22 2021-05-21 抗SARS-CoV-2刺突蛋白单克隆抗体

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010442784 2020-05-22
CN202010442784.9 2020-05-22

Publications (1)

Publication Number Publication Date
WO2021233433A1 true WO2021233433A1 (fr) 2021-11-25

Family

ID=78707715

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/095228 WO2021233433A1 (fr) 2020-05-22 2021-05-21 Anticorps monoclonal anti-protéine de spicule du sars-cov-2

Country Status (2)

Country Link
CN (1) CN115698058A (fr)
WO (1) WO2021233433A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115960218A (zh) * 2022-09-30 2023-04-14 中国医学科学院病原生物学研究所 一种抗新型冠状病毒的抗体及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111153991A (zh) * 2020-02-26 2020-05-15 北京博奥森生物技术有限公司 一种人SARS-CoV-2单克隆抗体及其制备方法和应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111153991A (zh) * 2020-02-26 2020-05-15 北京博奥森生物技术有限公司 一种人SARS-CoV-2单克隆抗体及其制备方法和应用

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHEN XIANGYU; LI REN; PAN ZHIWEI; QIAN CHUNFANG; YANG YANG; YOU RENRONG; ZHAO JING; LIU PINGHUANG; GAO LEIQIONG; LI ZHIRONG; HUANG: "Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor", CELLULAR, NATURE PUBLISHING GROUP UK, LONDON, vol. 17, no. 6, 20 April 2020 (2020-04-20), London, pages 647 - 649, XP037433894, ISSN: 1672-7681, DOI: 10.1038/s41423-020-0426-7 *
CHUNYAN WANG, LI WENTAO, DRABEK DUBRAVKA, OKBA NISREEN M. A., VAN HAPEREN RIEN, OSTERHAUS ALBERT D. M. E., VAN KUPPEVELD FRANK J. : "A human monoclonal antibody blocking SARS-CoV-2 infection", NATURE COMMUNICATIONS, vol. 11, no. 1, 2251, XP055737066, DOI: 10.1038/s41467-020-16256-y *
JIANG, S.B. ET AL.: "Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses", TRENDS IN IMMUNOLOGY, vol. 41, no. 5, 2 April 2020 (2020-04-02), pages 355 - 359, XP055694104, DOI: 10.1016/j.it.2020.03.007 *
TIAN, X.L. ET AL.: "Potent Binding of 2019 Novel Coronavirus Spike Protein by a SARS Coronavirus-specific Human Monoclonal Antibody", EMERGING MICROBES & INFECTION S, vol. 9, no. 1, 17 February 2020 (2020-02-17), pages 382 - 385, XP055736759, DOI: 10.1080/22221751.2020.1729069 *
XIUYUAN OU, LIU YAN, LEI XIAOBO, LI PEI, MI DAN, REN LILI, GUO LI, GUO RUIXUAN, CHEN TING, HU JIAXIN, XIANG ZICHUN, MU ZHIXIA, CHE: "Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV", NATURE COMMUNICATIONS, vol. 11, no. 1, 1620, XP055724997, DOI: 10.1038/s41467-020-15562-9 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115960218A (zh) * 2022-09-30 2023-04-14 中国医学科学院病原生物学研究所 一种抗新型冠状病毒的抗体及其用途
CN115960218B (zh) * 2022-09-30 2024-02-06 中国医学科学院病原生物学研究所 一种抗新型冠状病毒的抗体及其用途

Also Published As

Publication number Publication date
CN115698058A (zh) 2023-02-03

Similar Documents

Publication Publication Date Title
CN111690058B (zh) 针对冠状病毒的具有中和活性的抗体及其用途
RU2765306C2 (ru) Антитело против в7-н3, его антигенсвязывающий фрагмент и их медицинское применение
US9428575B2 (en) Anti-granulysin antibodies and methods of use thereof
CN113150129B (zh) 抗新冠病毒SARS-CoV-2表面S2蛋白的单链抗体及其应用
JP2019516348A (ja) 重症熱性血小板減少症候群ウイルスの外膜糖タンパク質に結合する抗体及びその用途
WO2021218947A1 (fr) Anticorps monoclonal contre le nouveau coronavirus et son utilisation
US20120020980A1 (en) High affinity human antibodies to human cytomegalovirus (cmv) gb protein
WO2021147984A1 (fr) Anticorps anti-angptl3 et son utilisation
CN115724958B (zh) 抗诺如病毒gⅱ基因组衣壳蛋白vp1的单克隆抗体及其应用
EP4206224A1 (fr) Anticorps humain ou fragment de liaison à l'antigène de celui-ci dirigé contre une protéine de spicule de coronavirus
WO2021233433A1 (fr) Anticorps monoclonal anti-protéine de spicule du sars-cov-2
CN113817052A (zh) 抗SARS-CoV-2核衣壳蛋白单克隆抗体及其制备方法和用途
WO2022179535A1 (fr) Anticorps monoclonal contre la protéine nucléocapsidique du sars-cov-2, son procédé de préparation et son utilisation
WO2021238854A1 (fr) Anticorps monoclonal dirigé contre la protéine de spicule du sars-cov-2, son procédé de préparation et son utilisation
CN115087667B (zh) 特异性结合SARS-CoV-2的抗原结合蛋白
WO2022068895A1 (fr) Anticorps monoclonal dirigé contre le domaine extracellulaire de la protéine de spicule du sars-cov-2, et son utilisation
WO2023046057A1 (fr) Anticorps monoclonal dirigé contre le mutant l452r de protéine de spicule de sars-cov-2 et son utilisation
WO2023046039A1 (fr) Anticorps monoclonal de protéine de spicule e484q anti-sars-cov-2 et son utilisation
US20230159652A1 (en) Transferrin receptor 1 targeting for carcinogenesis prevention
WO2022170983A1 (fr) Anticorps anti-coronavirus, procédé de criblage associé, composition pharmaceutique le contenant et application correspondante
WO2023131262A1 (fr) Protéine de liaison à l'antigène spécifiquement liée au sars-cov-2
US20240067706A1 (en) Fully human broad-spectrum neutralizing antibody 76e1 against coronavirus, and use thereof
CN116419972A (zh) 抗SARS-CoV-2抗体及其应用
US20240124558A1 (en) Antibodies binding to sars-cov-2 virus and uses thereof
CN117603346A (zh) 全人源新型冠状病毒单克隆抗体及其应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21809225

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21809225

Country of ref document: EP

Kind code of ref document: A1